PFAS in Pharmaceutical Production Environments
Pharmaceutical manufacturing uses PFAS-containing materials including fluoropolymer tubing, gaskets, vessel linings, and membrane filters. Migration of PFAS from manufacturing equipment into drug products represents a pharmaceutical quality and safety concern.
Regulatory Oversight and GMP Requirements
FDA Good Manufacturing Practice (GMP) regulations require pharmaceutical manufacturers to demonstrate that equipment materials do not adversely affect product quality. PFAS contamination of injectable and oral drug products from manufacturing equipment is a potential GMP compliance issue.
Industry Testing and Qualification
Major pharmaceutical companies have begun PFAS extractables and leachables (E&L) testing for fluoropolymer manufacturing components. USP and ICH guidelines for extractables testing are being applied to PFAS characterization in drug product contact materials.
Regulatory Guidance Development
FDA is developing guidance on PFAS in pharmaceutical manufacturing as part of broader drug quality initiatives. EMA in Europe has issued preliminary guidance noting PFAS as part of elemental impurities and extractables regulatory frameworks.